Starling Oncology Institute, Inc. Common Stock
STLN
34 hedge funds and large institutions have $6.98M invested in Starling Oncology Institute, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 6 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
2.15% more ownership
Funds ownership: 25.12% → 27.27% (+2.2%)
13% less funds holding
Funds holding: 39 → 34 (-5)
21% less capital invested
Capital invested by funds: $8.83M → $6.98M (-$1.85M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cincinnati Insurance
Fairfield,
Ohio
|
+$553K |
| 2 |
TAS
TIFF Advisory Services
Radnor,
Pennsylvania
|
+$503K |
| 3 |
QFA
Quattro Financial Advisors
The Woodlands,
Texas
|
+$44.2K |
| 4 |
Bank of New York Mellon
New York
|
+$33.2K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$73.9K |
| 2 |
Renaissance Technologies
New York
|
-$70.2K |
| 3 |
Millennium Management
New York
|
-$50.2K |
| 4 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
-$8.27K |
| 5 |
Jane Street
New York
|
-$5.68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
26
Cresset Asset Management
Chicago,
Illinois
| $5.98K | – | – | – |
|
|
27
Jane Street
New York
| $5.85K | -$5.68K | -13,721 | -43% |
|
|
TSS
28
Two Sigma Securities
New York
| $5.56K | +$7.04K | +16,997 | New |
|
29
Qube Research & Technologies (QRT)
London,
United Kingdom
| $5.11K | – | – | – |
|
|
ANTB
30
AMG National Trust Bank
Greenwood Village,
Colorado
| $3.27K | – | – | – |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $2.88K | -$428 | -1,033 | -11% |
|
32
Bank of America
Charlotte,
North Carolina
| $882 | +$15 | +36 | +1% |
|
33
JP Morgan Chase
New York
| $56 | – | +1 | +0.6% |
|
34
Citigroup
New York
| $8 | -$6 | -15 | -38% |
|
|
TM
35
Triatomic Management
Palo Alto,
California
| – | -$369K | -802,965 | Closed |
|
|
36
Millennium Management
New York
| – | -$50.2K | -109,207 | Closed |
|
|
VPIM
37
Vanguard Personalized Indexing Management
Oakland,
California
| – | -$8.27K | -17,984 | Closed |
|
38
Mariner
Overland Park,
Kansas
| – | -$5.01K | -10,884 | Closed |
|
39
RhumbLine Advisers
Boston,
Massachusetts
| – | -$1K | -2,175 | Closed |
|
STLN Hedge Fund Activity: Q3 2024 in Review
34 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Institute, Inc. Common Stock (STLN) for Q3 2024, worth a combined $6.98M — down 21% from $8.83M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of STLN and 2 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 13 added.
The largest buyer was Cincinnati Insurance, adding an estimated $553K. The largest seller was Citadel Advisors, cutting an estimated $73.9K.
- 34 institutional investors held Starling Oncology Institute, Inc. Common Stock (STLN) as of Q3 2024, down from 39 in Q2 2024.
- Funds reported $6.98M of Starling Oncology Institute, Inc. Common Stock stock for Q3 2024, down 21% quarter-over-quarter.
- 2 funds opened new Starling Oncology Institute, Inc. Common Stock positions in Q3 2024 and 6 closed out, a net change of -4 holders.
- The largest Starling Oncology Institute, Inc. Common Stock buyer in Q3 2024 was Cincinnati Insurance, an estimated $553K added.
- The largest Starling Oncology Institute, Inc. Common Stock seller in Q3 2024 was Citadel Advisors, an estimated $73.9K sold.
Based on aggregated 13F filings for Q3 2024.